Headlines about Hologic (NASDAQ:HOLX) have been trending positive on Friday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hologic earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 47.5563021716995 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
A number of analysts recently issued reports on HOLX shares. Needham & Company LLC reissued a “buy” rating and set a $43.00 target price (down previously from $50.00) on shares of Hologic in a research report on Tuesday, May 1st. Goldman Sachs Group set a $43.00 target price on shares of Hologic and gave the stock a “buy” rating in a research report on Tuesday, April 17th. BTIG Research reissued a “buy” rating and set a $44.00 target price on shares of Hologic in a research report on Sunday, May 6th. TheStreet downgraded shares of Hologic from a “b-” rating to a “c-” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $44.87.
Shares of NASDAQ:HOLX opened at $39.57 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.26 and a quick ratio of 0.98. Hologic has a 52-week low of $35.10 and a 52-week high of $46.80. The company has a market capitalization of $10.85 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.87 and a beta of 0.86.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The company had revenue of $789.30 million during the quarter, compared to the consensus estimate of $781.23 million. During the same quarter last year, the company earned $0.50 earnings per share. Hologic’s revenue for the quarter was up 10.3% on a year-over-year basis. analysts anticipate that Hologic will post 2.23 EPS for the current fiscal year.
In other Hologic news, VP Karleen Marie Oberton sold 12,196 shares of the stock in a transaction that occurred on Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total value of $487,840.00. Following the completion of the sale, the vice president now owns 13,825 shares of the company’s stock, valued at $553,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter J. Valenti III sold 10,107 shares of the stock in a transaction that occurred on Tuesday, May 29th. The shares were sold at an average price of $38.52, for a total transaction of $389,321.64. The disclosure for this sale can be found here. 0.79% of the stock is owned by company insiders.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.